Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Inhaled Levofloxacin

Phase Three

Phase Three

Therapeutic Approach

Anti-Infective

Inhaled levofloxacin (Quinsair™) is a formulation of the antibiotic levofloxacin for the management of chronic lung infections caused by Pseudomonas aeruginosa and other bacteria.

Status

Inhaled levofloxacin has been approved in the European Union and Canada for adults with CF.  A Phase 3 trial in the United States has been completed.

Sponsor

The program is sponsored by Horizon Pharma and partially supported by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.



Contact us about Inhaled Levofloxacin >